Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation

S. Kimura, K. Oshima, S. Okuda, K. Sato, M. Sato, K. Terasako, H. Nakasone, S. Kako, Rie Yamazaki, Y. Tanaka, A. Tanihara, T. Higuchi, J. Nishida, Y. Kanda

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We investigated the serial changes in the blood CsA concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n=12). The microemulsion form of CsA, Neoral, was started at twice the last dose in intravenous infusion in two equally divided doses. The area under the concentration-time curve during oral administration (AUC PO) was significantly higher than the AUC during intravenous infusion (AUC IV) (median 7508 vs 6705 ng/ml × h, P=0.050). The median bioavailability of Neoral, defined as (AUC PO /DOSE PO) divided by (AUC IV /DOSE IV), was 0.685 (range, 0.45-1.04). Concomitant administration of oral voriconazole (n=4) significantly increased the bioavailability of Neoral (median 0.87 vs 0.54, P=0.017), probably due to the inhibition of gut CYP3A4 by voriconazole. Although the conversion from intravenous to oral administration of CsA at a ratio of 1:2 seemed to be appropriate in most patients, a lower conversion ratio may be better in patients taking oral voriconazole. To obtain a similar AUC, the target trough concentrations during twice-daily oral administration should be halved compared with the target concentration during continuous infusion.

Original languageEnglish
Pages (from-to)1088-1094
Number of pages7
JournalBone Marrow Transplantation
Volume45
Issue number6
DOIs
Publication statusPublished - 2010 Jun 1
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Intravenous Infusions
Area Under Curve
Oral Administration
Pharmacokinetics
Cyclosporine
Biological Availability
Cytochrome P-450 CYP3A
Hematopoietic Stem Cells
Transplants
Voriconazole

Keywords

  • bioavailability
  • CsA
  • drug interaction
  • pharmacokinetics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. / Kimura, S.; Oshima, K.; Okuda, S.; Sato, K.; Sato, M.; Terasako, K.; Nakasone, H.; Kako, S.; Yamazaki, Rie; Tanaka, Y.; Tanihara, A.; Higuchi, T.; Nishida, J.; Kanda, Y.

In: Bone Marrow Transplantation, Vol. 45, No. 6, 01.06.2010, p. 1088-1094.

Research output: Contribution to journalArticle

Kimura, S, Oshima, K, Okuda, S, Sato, K, Sato, M, Terasako, K, Nakasone, H, Kako, S, Yamazaki, R, Tanaka, Y, Tanihara, A, Higuchi, T, Nishida, J & Kanda, Y 2010, 'Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation', Bone Marrow Transplantation, vol. 45, no. 6, pp. 1088-1094. https://doi.org/10.1038/bmt.2009.316
Kimura, S. ; Oshima, K. ; Okuda, S. ; Sato, K. ; Sato, M. ; Terasako, K. ; Nakasone, H. ; Kako, S. ; Yamazaki, Rie ; Tanaka, Y. ; Tanihara, A. ; Higuchi, T. ; Nishida, J. ; Kanda, Y. / Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. In: Bone Marrow Transplantation. 2010 ; Vol. 45, No. 6. pp. 1088-1094.
@article{4a269377a27f4b56b4dd5768e53eddc7,
title = "Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation",
abstract = "We investigated the serial changes in the blood CsA concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n=12). The microemulsion form of CsA, Neoral, was started at twice the last dose in intravenous infusion in two equally divided doses. The area under the concentration-time curve during oral administration (AUC PO) was significantly higher than the AUC during intravenous infusion (AUC IV) (median 7508 vs 6705 ng/ml × h, P=0.050). The median bioavailability of Neoral, defined as (AUC PO /DOSE PO) divided by (AUC IV /DOSE IV), was 0.685 (range, 0.45-1.04). Concomitant administration of oral voriconazole (n=4) significantly increased the bioavailability of Neoral (median 0.87 vs 0.54, P=0.017), probably due to the inhibition of gut CYP3A4 by voriconazole. Although the conversion from intravenous to oral administration of CsA at a ratio of 1:2 seemed to be appropriate in most patients, a lower conversion ratio may be better in patients taking oral voriconazole. To obtain a similar AUC, the target trough concentrations during twice-daily oral administration should be halved compared with the target concentration during continuous infusion.",
keywords = "bioavailability, CsA, drug interaction, pharmacokinetics",
author = "S. Kimura and K. Oshima and S. Okuda and K. Sato and M. Sato and K. Terasako and H. Nakasone and S. Kako and Rie Yamazaki and Y. Tanaka and A. Tanihara and T. Higuchi and J. Nishida and Y. Kanda",
year = "2010",
month = "6",
day = "1",
doi = "10.1038/bmt.2009.316",
language = "English",
volume = "45",
pages = "1088--1094",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation

AU - Kimura, S.

AU - Oshima, K.

AU - Okuda, S.

AU - Sato, K.

AU - Sato, M.

AU - Terasako, K.

AU - Nakasone, H.

AU - Kako, S.

AU - Yamazaki, Rie

AU - Tanaka, Y.

AU - Tanihara, A.

AU - Higuchi, T.

AU - Nishida, J.

AU - Kanda, Y.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - We investigated the serial changes in the blood CsA concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n=12). The microemulsion form of CsA, Neoral, was started at twice the last dose in intravenous infusion in two equally divided doses. The area under the concentration-time curve during oral administration (AUC PO) was significantly higher than the AUC during intravenous infusion (AUC IV) (median 7508 vs 6705 ng/ml × h, P=0.050). The median bioavailability of Neoral, defined as (AUC PO /DOSE PO) divided by (AUC IV /DOSE IV), was 0.685 (range, 0.45-1.04). Concomitant administration of oral voriconazole (n=4) significantly increased the bioavailability of Neoral (median 0.87 vs 0.54, P=0.017), probably due to the inhibition of gut CYP3A4 by voriconazole. Although the conversion from intravenous to oral administration of CsA at a ratio of 1:2 seemed to be appropriate in most patients, a lower conversion ratio may be better in patients taking oral voriconazole. To obtain a similar AUC, the target trough concentrations during twice-daily oral administration should be halved compared with the target concentration during continuous infusion.

AB - We investigated the serial changes in the blood CsA concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n=12). The microemulsion form of CsA, Neoral, was started at twice the last dose in intravenous infusion in two equally divided doses. The area under the concentration-time curve during oral administration (AUC PO) was significantly higher than the AUC during intravenous infusion (AUC IV) (median 7508 vs 6705 ng/ml × h, P=0.050). The median bioavailability of Neoral, defined as (AUC PO /DOSE PO) divided by (AUC IV /DOSE IV), was 0.685 (range, 0.45-1.04). Concomitant administration of oral voriconazole (n=4) significantly increased the bioavailability of Neoral (median 0.87 vs 0.54, P=0.017), probably due to the inhibition of gut CYP3A4 by voriconazole. Although the conversion from intravenous to oral administration of CsA at a ratio of 1:2 seemed to be appropriate in most patients, a lower conversion ratio may be better in patients taking oral voriconazole. To obtain a similar AUC, the target trough concentrations during twice-daily oral administration should be halved compared with the target concentration during continuous infusion.

KW - bioavailability

KW - CsA

KW - drug interaction

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=77954861045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954861045&partnerID=8YFLogxK

U2 - 10.1038/bmt.2009.316

DO - 10.1038/bmt.2009.316

M3 - Article

C2 - 19898510

AN - SCOPUS:77954861045

VL - 45

SP - 1088

EP - 1094

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -